How precision and personalized medicine M&A performed in the pharmaceutical industry in Q2 2023

In value terms, precision and personalized medicine-related deal activity decreased by 85% in Q2 2023 compared with the previous quarter’s total of $1.5bn and rose by 145% as compared to Q2 2022. Related deal volume decreased by 14% in Q2 2023 versus the previous quarter and was 200% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Centerview Partners; Ladenburg Thalmann Financial Services; Moelis & Co with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Cooley; Dechert; Dentons Bingham Greenbaum with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.